Evidence map›Paper›PMID 26856213›Full record

Trial reportAmerican heart journal2016

Evaluation of a provocative dyspnea severity score in acute heart failure.

Omar F AbouEzzeddine, Anuradha Lala, Prateeti P Khazanie, Ravi Shah, Jennifer E Ho, Horng H Chen, Peter S Pang, Steven E McNulty, Kevin J Anstrom, Adrian F Hernandez and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in American heart journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. EJNMMI physics · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Omar F AbouEzzeddineMayo Clinic, Rochester, MN. Electronic address: Abouezzeddine.Omar@mayo.edu.
Anuradha LalaBrigham and Women's Hospital, Boston, MA; Mount Sinai Hospital, Icahn School of Medicine, New York, NY.
Prateeti P KhazanieDuke University Medical Center and Duke Heart Center, Durham, NC.
Ravi ShahMassachusetts General Hospital, Boston, MA.
Jennifer E HoBoston University School of Medicine, Boston, MA.
Horng H ChenMayo Clinic, Rochester, MN.
Peter S PangIndiana University School of Medicine, Indianapolis, IN.
Steven E McNultyDuke Clinical Research Institute, Durham, NC.
Kevin J AnstromDuke Clinical Research Institute, Durham, NC.
Adrian F HernandezDuke Clinical Research Institute, Durham, NC.
Margaret M RedfieldMayo Clinic, Rochester, MN.
NHLBI Heart Failure Clinical Research Network

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Heart Failure Clinical Research Network Coordinating CenterU10HL084904 · NHLBI · DUKE UNIVERSITY · PI ANSTROM, KEVIN J, HERNANDEZ, ADRIAN · 2012 to 2018
$38.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Research Desogn and Biostatistics CoreU54MD007588 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI HENRY-AKINTOBI, TABIA · 2012 to 2018
$24.8M
Heart Failure Clinical Research Network - DCCU01HL084904 · NHLBI · DUKE UNIVERSITY · PI LEE, KERRY L · 2006 to 2011
$19.8M
CARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7M
Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
Mayo Heart Failure Regional Clinical CenterU10HL110262 · NHLBI · MAYO CLINIC ROCHESTER · PI REDFIELD, MARGARET M · 2012 to 2018
$3.6M
Heart Failure Clinical Research Network Regional Clinical Center (U10)U10HL110312 · NHLBI · DUKE UNIVERSITY · PI FELKER, GARY M · 2012 to 2018
$3.5M
SALsalate to Improve Exercise toleraNce and LVDD in T2dm-DHF (SALIENT-DHF trial)U10HL110309 · NHLBI · WASHINGTON UNIVERSITY · PI DAVILA-ROMAN, VICTOR G., MANN, DOUGLAS L · 2012 to 2018
$3.5M
NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR000439NCATS NIH HHS UL1 TR000454NCRR NIH HHS UL1 RR025008NHLBI NIH HHS T32 HL007111NHLBI NIH HHS T32 HL069749NHLBI NIH HHS U01 HL084861NHLBI NIH HHS U01 HL084889NHLBI NIH HHS U01 HL084890NHLBI NIH HHS U01 HL084891NHLBI NIH HHS U01 HL084904NHLBI NIH HHS U01 HL084907NHLBI NIH HHS U01 HL084931NHLBI NIH HHS U10 HL084904NHLBI NIH HHS U10 HL110262NHLBI NIH HHS U10 HL110297NHLBI NIH HHS U10 HL110302NHLBI NIH HHS U10 HL110309NHLBI NIH HHS U10 HL110312NHLBI NIH HHS U10 HL110336NHLBI NIH HHS U10 HL110337NHLBI NIH HHS U10 HL110338NHLBI NIH HHS U10 HL110342NIMHD NIH HHS U54 MD007588
6 · The paper itself

Abstract

backgroundThe acute heart failure (AHF) Syndromes International Working Group proposed that dyspnea be assessed under standardized, incrementally provocative maneuvers and called for studies to assess the feasibility of this approach. We sought to assess the feasibility and statistical characteristics of a novel provocative dyspnea severity score (pDS) versus the traditional dyspnea visual analog scale (DVAS) in an AHF trial.

methodsAt enrollment, 24, 48 and 72hours, 230 ROSE-AHF patients completed a DVAS. Dyspnea was then assessed with 5-point Likert dyspnea scales administered during 4 stages (A: upright-with O2, B: upright-without O2, C: supine-without O2 and D: exercise-without O2). Patients with moderate or less dyspnea were eligible for the next stage.

resultsAt enrollment, oxygen withdrawal and supine provocation were highly feasible (≥97%), provoking more severe dyspnea (≥1 Likert point) in 24% and 42% of eligible patients, respectively. Exercise provocation had low feasibility with 38% of eligible patients unable to exercise due to factors other than dyspnea. A pDS was constructed from Likert scales during the 3 feasible assessment conditions (A-C). Relative to DVAS, the distribution of the pDS was more skewed with a high "ceiling effect" at enrollment (23%) limiting sensitivity to change. Change in pDS was not related to decongestion or 60-day outcomes.

conclusionsAlthough oxygen withdrawal and supine provocation are feasible and elicit more severe dyspnea, exercise provocation had unacceptable feasibility in this AHF cohort. The statistical characteristics of a pDS based on feasible provocation measures do not support its potential as a robust dyspnea assessment tool in AHF.

Indexed as

Acute DiseaseAgedBiomarkersDyspneaExercise TestFeasibility StudiesFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPrognosisProspective StudiesBiomarkersNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)

Identifiers

PMID26856213
PMCPMC4748181

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.